Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the nine analysts that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $20.29.

Several analysts recently commented on TRVI shares. Wall Street Zen cut Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. Needham & Company LLC restated a "buy" rating and issued a $24.00 target price on shares of Trevi Therapeutics in a report on Tuesday, May 20th. D. Boral Capital restated a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Monday, June 2nd. Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. Finally, HC Wainwright started coverage on Trevi Therapeutics in a report on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price for the company.

Trevi Therapeutics Stock Performance

Shares of TRVI traded down $0.04 during trading hours on Thursday, hitting $5.62. 2,232,762 shares of the stock were exchanged, compared to its average volume of 1,396,705. Trevi Therapeutics has a 12-month low of $2.36 and a 12-month high of $7.48. The company has a market cap of $659.17 million, a price-to-earnings ratio of -12.49 and a beta of 0.59. The stock's 50-day moving average price is $6.33 and its two-hundred day moving average price is $5.35.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04. On average, research analysts expect that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Hedge Funds Weigh In On Trevi Therapeutics

A number of hedge funds have recently modified their holdings of the business. Rhumbline Advisers grew its holdings in shares of Trevi Therapeutics by 13.3% during the 1st quarter. Rhumbline Advisers now owns 90,482 shares of the company's stock worth $569,000 after purchasing an additional 10,608 shares during the period. Strs Ohio purchased a new position in shares of Trevi Therapeutics during the 1st quarter worth $52,000. Acorn Capital Advisors LLC grew its holdings in shares of Trevi Therapeutics by 7.2% during the 1st quarter. Acorn Capital Advisors LLC now owns 2,144,844 shares of the company's stock worth $13,491,000 after purchasing an additional 143,796 shares during the period. Exome Asset Management LLC purchased a new position in shares of Trevi Therapeutics during the 1st quarter worth $1,030,000. Finally, Octagon Capital Advisors LP purchased a new position in shares of Trevi Therapeutics during the 1st quarter worth $20,895,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.